Acesso livre
Acesso livre

Infectologia

[Preprint] Revisão sistemática | Duração da efetividade das vacinas contra infecção por SARS-CoV-2 e COVID-19 – “Na maioria dos estudos, a efetividade contra COVID-19 grave continua alta (>70%) após 6 meses de vacinação completa, embora de fato haja alguma queda (na média, 8 a 10 pontos percentuais) entre 1 e 6 meses depois da vacinação.”

23 Nov, 2021 | 15:55h

Duration of Effectiveness of Vaccines Against SARS-CoV-2 Infection and COVID-19 Disease: Results of a Systematic Review and Meta-Regression – Preprints with The Lancet – SSRN

Conteúdos relacionados:

Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine.

China’s COVID vaccines have been crucial — now immunity is waning.

[Preprint] Breakthrough SARS-CoV-2 infections in 620,000 U.S. Veterans, February 1, 2021 to August 13, 2021 – “Vaccine protection declined by mid-August 2021, decreasing from 91.9% in March to 53.9%”.

Observational study in Qatar showed the effectiveness of Pfizer vaccine against any SARS-CoV-2 infection dropped to 20% in months 5 through 7 after the second dose, but effectiveness against severe Covid-19 remained high.

Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

M-A | Colchicina não reduz a gravidade da COVID-19 nem evita o risco de morte.

23 Nov, 2021 | 15:53h

Comunicado de imprensa: Gout drug colchicine doesn’t lessen COVID-19 severity or stave off risk of death – BMJ

Estudo original: Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials – RMD Open

Conteúdos relacionados:

Estudo populacional na França não mostrou incidência aumentada de infarto agudo do miocárdio, AVC e embolia pulmonar após uso da vacina da Pfizer.

23 Nov, 2021 | 15:51h

Myocardial Infarction, Stroke, and Pulmonary Embolism After BNT162b2 mRNA COVID-19 Vaccine in People Aged 75 Years or Older – JAMA

Cientistas perplexos e cautelosos, enquanto a África parece evitar o desastre da COVID.

23 Nov, 2021 | 15:50h

Scientists mystified, wary, as Africa avoids COVID disaster – Associated Press

O paciente com COVID-19 na UTI cirúrgica.

23 Nov, 2021 | 15:49h

The COVID-19 Patient in the Surgical Intensive Care Unit – Surgical Clinics of North America

Diretriz IDSA sobre o tratamento de infecções por Gram-negativos resistentes a antibióticos.

23 Nov, 2021 | 15:46h

IDSA Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections – Infectious Diseases Society of America

 

Comentário no Twitter

 

Consciência sobre antibióticos: uma visão geral de evidências Cochrane.

23 Nov, 2021 | 15:37h

Antibiotic Awareness: a round-up of Cochrane evidence – Cochrane Library

 

Comentário no Twitter

 

Revisão | Prevenção de infecções emergentes em crianças.

23 Nov, 2021 | 15:33h

Prevention of Emerging Infections in Children – Pediatric Clinics of North America

Atualizações recentes sobre a gestão de antibióticos para antibioticoterapia parenteral ambulatorial.

23 Nov, 2021 | 15:31h

Recent Updates in Antimicrobial Stewardship in Outpatient Parenteral Antimicrobial Therapy – Current Infectious Disease Reports

Nos EUA, FDA libera doses de reforço da vacina contra COVID-19 para adultos com mais de 18 anos – Pfizer e Moderna 6 meses depois da 2ª dose.

22 Nov, 2021 | 09:40h

United States FDA Clears COVID Vaccine Boosters for All Adults Over 18 – Pfizer & Moderna 6 Months After Second Jab – Health Policy Watch

Ver também:

FDA expands emergency authorization for Covid-19 booster shots to all adults – STAT

FDA, CDC advisors approve COVID boosters for all US adults – CIDRAP

FDA Approves Both Pfizer, Moderna Boosters for All Adults – HealthDay

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.